2022 / 04

Next Paper
DOI: 10.24075/brsmu.2022.044

ORIGINAL RESEARCH

Experience of Stanford neuromodulation therapy in patients with treatment-resistant depression

Poydasheva AG1, Bakulin IS1, Sinitsyn DO1, Zabirova AH1, Suponeva NA1, Maslenikov NV2, Tsukarzi EE2, Mosolov SN2,3, Piradov MA1
About authors

1 Research Center of Neurology, Moscow, Russia

2 Moscow Research Institute of Psychiatry, Moscow, Russia

3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Correspondence should be addressed: Alexandra G. Poydasheva
Volokolamskoe shosse, 80, Moscow, 125367, Russia; ur.ygoloruen@avehsadyop

About paper

Author contribution: Poydasheva AG, Bakulin IS, Mosolov SN — study planning and design; Poydasheva AG, Zabirova AH — literature review; Poydasheva AG, Sinitsyn DO, Maslenikov NV, Tsukarzi EE — data acquisition and analysis; all authors — data interpretation; Poydasheva AG, Sinitsyn DO — manuscript writing; all authors — manuscript editing.

Compliance with ethical standards: the research protocol was approved by the Ethics Committee at the Research Center of Neurology (protocol № 11-1/21 of 22 December 2021); the study was conducted in accordance with the principles of the Declaration of Helsinki; the informed consent was submitted by all study participants.

Received: 2022-08-08 Accepted: 2022-08-22 Published online: 2022-08-30
|
Fig. 1. Visualization of the functional connectivity (FC) analysis data and target selection in patients. Color shows FC values between the subgenual cingulate and the visualized cortical areas. The target is marked with a green tag
Fig. 2. Scheme of the Stanford Neuromodulation Therapy (SNT) protocol
Fig. 3. Dynamics of depressive symptoms: individual data
Table. Clinical and demographic data of the patients enrolled
Note: MADRS — Montgomery–Asberg Depression Rating Scale; MSM — Maudsley Staging Method.